CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Tuesday reported a loss of $109.2 million in its fourth quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.24.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.28 per share.
The biopharmaceutical company posted revenue of $258.4 million in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $249.4 million.
For the year, the company reported a loss of $703.5 million, or $8.03 per share. Revenue was reported as $933 million.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SRPT at https://www.zacks.com/ap/SRPT
Copyright © 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.